23.4 C
New York
Monday, June 15, 2026

Tag: nerve

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

NEWBEAUTY RELEASES ‘THE STATE OF AESTHETICS: BY THE NUMBERS SUMMER 2025’

CRANBURY, N.J., July 22, 2025 /PRNewswire/ -- NewBeauty , the definitive authority on all things beauty, has announced the release of The State of Aesthetics: By the...

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Global Semiconductor Market Size Worth USD 1.2 Trillion by 2034| Sales $57 Billion Recorded in April 2025

According to Precedence Research, the global semiconductor market size was valued at USD 584.17 billion in 2024 and is projected to be worth around USD 1.2 trillion by 2034, reflecting a solid CAGR of 7.54% from 2025 to 2034.
According to Precedence Research, the global semiconductor market size was valued at USD 584.17 billion in 2024 and is projected to be worth around USD 1.2 trillion by 2034, reflecting a solid CAGR of 7.54% from 2025 to 2034.

38 Special Mark 50th Anniversary With First Album in 20 Years, Milestone, out September 19

Watch the Music Video For Lead Single"All I Haven't Said" Touring This Summer and Fall Including Shows With KANSAS NEW YORK, July 11, 2025 /PRNewswire/ -- Today, 38...

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.

New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model

Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner
Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner

Native Hydrate Variety Pack Delivers Sugar-Free Hydration with Full Electrolyte Profile and Nine Essential Amino Acids

Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.
Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.

Johnson & Johnson Launches VARIPULSE™ Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...

Luma Nutrition Magnesium Glycinate Surpasses 10,000 Monthly Sales on Amazon

Los Angeles, CA , July 07, 2025 (GLOBE NEWSWIRE) -- Luma Nutrition is proud to announce that its flagship product, Luma Nutrition Magnesium Glycinate 1000mg, has officially surpassed 10,000 units sold per month on Amazon. As one of the best magnesium glycinate supplements available in 2025, this high-absorption formula continues to earn praise for its purity, effectiveness, and ability to support restful sleep, mental clarity, and full-body relaxation. 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNerve